Immunoneuroendocrine communication network and the regulation of the homeostasis: The use of hormones and neurohormones as immunotherapy;La red de comunicación neuroinmunoendocrina y la regulación de la homeostasis: El uso de hormonas y neurohormonas como inmunoterapia

Revista de Investigacion Clinica

Volumn 54, Issue 6, 2002, Pages 542-549

  Arteaga, Marcala ^a   Chavarría, Anahi ^b   Morales Montor, Jorge ^b  

^a DEPARTAMENTO DE QUÍMICA   (Mexico)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Homeotasis; Immunoendocrine; Interactions; Regulation

Indexed keywords

CHORIONIC GONADOTROPIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; ESTRADIOL; GROWTH HORMONE; HORMONE; HYDROCORTISONE; LIGAND; MELATONIN; NEUROHORMONE; NEUROTRANSMITTER; OXYTOCIN; PRASTERONE; PROLACTIN; RECEPTOR; TESTOSTERONE; VASOACTIVE INTESTINAL POLYPEPTIDE;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN BLOOD LEVEL; MAMMAL; NEUROENDOCRINOLOGY; NEUROTRANSMISSION; REVIEW; VERTEBRATE;

HOMEOSTASIS; HORMONES; HUMANS; IMMUNOTHERAPY; NEUROIMMUNOMODULATION; NEUROSECRETORY SYSTEMS; NEUROTRANSMITTER AGENTS;

EID: 0036881104     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Besedovsky HO, Del rey A. Immune-neuroendocrine interactions: factors and hypotheses. Endo Revs 1996; 17: 64-102.
2. Coutinho A, Hori S, Carvalho T, Caramalho I, Demengeot J. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses. Immunol Rev 2001; 182: 89-98.
3. Armstrong MD, Klein JR. Immune-endocrine interactions of the hypothalamus-pituitary-thyroid axis: integration, communication and homeostasis. Arch Immunot Ther Exp (Warsz) 2001; 49: 231-7.
4. Savina NP. Immunoendocrine homeostasis in mice after local irradiation of immune and endocrine system organs Radiats Biol Radioecol 1996; 36: 68-77.
5. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995; 13: 307-38.
6. Jurankova E. Immunoendocrine interactions and autoimmune diseases. Bratisl Lek Listy 1994; 95: 51-6.
7. Rook GA, Hernandez-Pando R, Lightman SL. Hormones, peripherally activated pro-hormones and regulation of the Th1/Th2 balance. Immunol Today 1994; 15: 301-3.
8. Chikanza IC, Grossman AB. Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheum Dis Clin North Am 2000; 26: 693-711.
9. Morales-Montor J. Does host neuroendocrine system regulates the immune response to parasites? Mod Asp Immunobiol 2002; 3: 110-16.
10. Sterzl J, Rehacek Z, Cudlin J. Regulation of the immune response by ergot alkaloids. Czech Med 1987; 10: 90-8.
11. Cavallotti C, Artico N and Cavallotti D. Occurrence of adrenergic nerve fibers and of noradrenaline in thymus gland of juvenile and aged rats. Immunol Lett 1999; 70: 53-62.
12. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 135-162.
13. Del Rey A, Besedovsky HO. The cytokine-HPA axis circuit contributes to prevent or moderate autoimmune processes. Z Rheumatol 2000; 59 Suppl 2: II/31-5.
14. Garzetti GG, Ciavattini A, Provinciali M, Muzzioli M, Di Stefano G, del Rey A, Besedovsky HO. The cytokine-HPA axis feed-back circuit. 2000; Z Rheumatol: 59 Suppl 2:II/26-30.
15. Peck R. Neuropeptides modulating macrophage function. Ann NY Acad Sci 1987; 496: 264-70.
16. Johnson RW, Arkins S, Dantzer R, Kelley KW. Hormones, lymphohemopoietic cytokines and the neuroimmune axis. Comparative Biochemistry Physiology 1997; 3: 183-201.
17. Verthelyi D. Sex hormones as immunomodulators in health and disease. Intl Immuno-pharmacol 2001; 1: 983-93.
18. Besedovsky HO, del Rey A. Introduction: immune-neuroendocrine network. Front Horm Res 2002; 29: 1-14.
19. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosc Biobehav Rev 2000; 24: 627-38.
20. Reichlin S. Neuroendocrinology of infection and the innate immune system. Recent Prog Horm Res 1999; 54: 133-81.
21. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol 2001; 79: 350-7.
22. Rook GA, Hernandez-Pando R. Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Novartis Found Symp 1998; 217: 73-87.
23. Da Silva JAP. Sex hormones and glucocorticoids: Interactions with the immune system. Ann N Y Acad Sci 1999; 876: 102-118.
24. Berczi I. The stress concept and neuroimmunoregulation in modern biology. Ann N Y Acad Sci 1998; 30: 3-12.
25. Clerici M, Galli M, Bosis S, Gervasoni C, Moroni M, Norbiato G. Immuno endocrinologic abnormalities in human immunodeficiency virus infection. Ann N Y Acad Sci 2000; 917: 956-61.
26. Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, Job T, Itoh M, Kakumu S. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol. 2001; 36: 544-51.
27. Mazzeo RS. Aging, immune function, and exercise: hormonal regulation. Int J Sports Med. 2000; 21: S10-23.
28. Rook GA, Stanford JL. Adjuvants, endocrines and conserved epitopes; factors to consider when designing "therapeutic vaccines". Int J Immunopharmacol 1995; 17: 91-102.
29. Mascaruccil P, Taub D, Saccani S, Paloma MA, Dawson H, Roth GS, Ingram DK, Lane MA. Age-related changes in cytokine production by leukocytes in rhesus monkeys. Aging (Milano) 2000; 13: 85-94.
30. De Swert LF. Risk factors for allergy. Eur J Pediatr 1999; 158: 89-94.
31. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999; 189: 803-10.
32. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-76.
33. Majumder B, Biswas R, Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer 2002; 97: 493-500.
34. Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendorfer A, Tscherne H, Pape HC. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med. 2001; 29: 380-4.
35. Maier U. Hormone profile in the aging man. Wien Med Wochenschr 2001;151: 422-5.
36. Robinzon B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford) 1999; 38: 488-95.
37. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 in astrocytes. Int J Dev Neurosci 1999; 17: 765-75.
38. Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology 1995; 52: 163-6.
39. Saas P, Tiberghien P. Dendritic cells: to where do they lead? Transplantation 2002; 15: S12-5.
40. Fallon PG, Richardson EJ, Jones FM, Dunne DW. Dehydroepiandrosterone sulfate treatment of mice modulates infection with Schistosoma mansoni. Clin Diagn Lab Immunol 1998; 5: 251-3.
41. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol 1996; 31: 81-95.
42. Karakalis K, Sano H, Redwin J, Litswak S, Wilder RL, and Chorusos GP. Autocrine or paracrine actions of corticotrophin-releasing hormone in vivo. Science 1991; 254: 421-3.
43. Arakawa K, Akami T, Okamoto M, Oka T, Nagase H, Matsumoto S. The immunosupressive effect of σ-opiod receptor antagonist on rat renal allograft survival. Transplantation 2001; 53: 953-9.